The short version of human growth hormone fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-09-24. Anything still debated is marked as such rather than presented as settled.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
===== Extraterrestrial origin of homochirality ===== Some analyses of organic molecules in extraterrestrial materials, such as carbonaceous chondrite meteorites and asteroids, identified small enantiomeric enrichments in a few L-amino acids and D-sugars, leading to the proposition that initial enantiomeric bias could have been seeded on Earth from space. That the enantiomeric biases measured in meteorites and astroids were consistent with that found in biology added credence to this idea, and experimental work showed plausible mechanisms for creating this enantiomeric bias in extraterrestrial materials. It was hypothesized that circularly polarized light originating from Mie scattering on aligned interstellar dust particles may trigger the formation of an enantiomeric excess within chiral material in space. Interstellar and near-stellar magnetic fields can align dust particles in this fashion. Another speculation (the Vester-Ulbricht hypothesis) suggests that fundamental chirality of physical processes such as that of the beta decay (see Parity violation) leads to slightly different half-lives of biologically relevant molecules. The amino acids in asteroids Bennu and Ryugu show no chiral bias. The Murchinson meteorite contained only racemic amino acids.
== Illicit production == Illicit production and sale of etonitazene has been limited. Identified on the Moscow illegal drug market in 1998, it was primarily smoked in laced cigarettes. A chemist at Morton Thiokol synthesized the compound for his own use. The drug was produced in Russia in 1996 and sold as 'Chinese Dwarf'. The drug resulted in an unconfirmed number of deaths due to its uncertain potency. Etonitazene appears to have a steep dose-response curve, and unpredictable pharmacokinetics especially when injected, in a similar manner to some other potent opioids such as dextromoramide, which may cause etonitazene to be especially hazardous when compared to opioids of similar potency such as fentanyl.
The FDA approved pembrolizumab for adults with resectable locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1 as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy with or without cisplatin after surgery, and then as a single agent. It is the first approval for head and neck squamous cell carcinoma in six years and the first overall perioperative approval for locally advanced head and neck squamous cell carcinoma. In November 2025, the US FDA approved pembrolizumab or pembrolizumab and berahyaluronidase alfa with enfortumab vedotin as neoadjuvant treatment followed by adjuvant treatment after cystectomy for adults with muscle invasive bladder cancer who are ineligible for cisplatin.
=== Manufacture === When the therapeutic potential of thiamazole was recognised in the late 1940s, a number of alternative routes were developed based, for example, on the use of 2-chloro-1,2-diethoxyethane as starting material, in a reaction with methylamine.
20th century developments in plant biochemistry have been driven by modern techniques of organic chemical analysis, such as spectroscopy, chromatography and electrophoresis. With the rise of the related molecular-scale biological approaches of molecular biology, genomics, proteomics and metabolomics, the relationship between the plant genome and most aspects of the biochemistry, physiology, morphology and behaviour of plants can be subjected to detailed experimental analysis. The concept originally stated by Gottlieb Haberlandt in 1902 that all plant cells are totipotent and can be grown in vitro ultimately enabled the use of genetic engineering experimentally to knock out a gene or genes responsible for a specific trait, or to add genes such as GFP that report when a gene of interest is being expressed. These technologies enable the biotechnological use of whole plants or plant cell cultures grown in bioreactors to synthesise pesticides, antibiotics or other pharmaceuticals, as well as the practical application of genetically modified crops designed for traits such as improved yield. Modern morphology recognises a continuum between the major morphological categories of root, stem (caulome), leaf (phyllome) and trichome. Furthermore, it emphasises structural dynamics. Modern systematics aims to reflect and discover phylogenetic relationships between plants. Modern molecular phylogenetics largely ignores morphological characters, relying on DNA sequences as data.
Sources: en.wikipedia.org
== Media career == Following Hird's retirement as a player from the Bombers at the end of the 2007 AFL season, he became a commentator and football analyst for Australian rules football on Fox Sports, a position which he held until he began his coaching career at the end of 2010. Hird also became a writer for Melbourne newspaper the Herald Sun. At the start of 2025, Hird joined the Nine Network, becoming a panellist on the Tuesday night edition of Footy Classified, as well as Sunday night program Footy Furnace.
The foreskin is the double-layered fold of tissue at the distal end of the human penis that covers the glans and the urinary meatus. Different amounts of skin can be removed during circumcision. The practice is differentiated from other surgeries for the treatment of phimosis or treatment-resistant infection by the complete removal of the preputial orifice.
Illinois Central Railroad number 51000 was built in the McComb, Mississippi shops with an aluminum superstructure to reduce weight with steel where required for strength and provided the standard dimensions, cushioned draft gear, easy-riding trucks, minimum 4 inches (10 cm) of insulation, adjustable ice bunker bulkheads and half-stage icing racks with forced air circulation through side wall flues and floor racks recommended by UFF&VA. Santa Fe Refrigerator Despatch number 13000 was built of stainless steel by the Consolidated Steel Corporation of Wilmington, California with convertible ice bunkers, side ventilation ducts, and axle-driven circulation fans. It was thought that stainless steel would better resist the corrosive deterioration resulting from salting the ice. The one-of-a-kind unit entered service as #13000, but was subsequently redesignated as #1300, and later given #4150 in 1955. The car spent most of its life in express service. Cost was cited as the reason no additional units were ordered. The car was dismantled at Clovis, New Mexico in February 1964. Pacific Fruit Express rebuilt two steel-sided ventilator refrigerator cars in their Los Angeles shops with aluminum car bodies to test the durability of lightweight alloys versus that of steel. It was hoped that weight savings (the units weighed almost 10,000 lb (4,536 kg) less than a like-sized all-steel car) and better corrosion resistance would offset the higher initial cost. Alcoa provided the body for number 44739, and Reynolds Aluminum Company provided number 45698.
Ground coffee in cans 100% Colombian (medium roast) Black Silk (dark roast), also available in decaf Brazilian blend (medium roast) Breakfast blend (mild roast) Classic roast (medium roast), also in decaf and half caff Coffeehouse blend (medium-dark roast) Country roast (medium-dark roast) French roast (medium-dark roast) Gourmet Supreme (medium-dark roast) House blend (medium roast) Special roast (medium roast) Folgers Noir, a line of dark roast coffees Simply Smooth, a mild roast coffee intended to be gentler on the stomach, also in decaf Simply Gourmet, a line of naturally flavored coffees Folgers Flavors, French vanilla and hazelnut flavored coffees, also available as decaf hazelnut Folgers Crystals, instant coffee available in regular and decaf Coffee Singles, single-serve packets Cappuccino instant mixes K-cup pods in a variety of roasts and flavors 1850, a premium brand launched in 2018 In Canada, Folgers is primarily available as Classic Roast and Mountain Roast. In the United Kingdom, Folgers Instant Crystals are available.
==== MeSH D08.811.739 – recombinases ==== MeSH D08.811.739.250 – holliday junction resolvases MeSH D08.811.739.500 – integrases MeSH D08.811.739.500.667 – transposases MeSH D08.811.739.500.667.500 – hiv integrase MeSH D08.811.739.650 – rec a recombinases MeSH D08.811.739.650.500 – rad51 recombinase MeSH D08.811.739.800 – transposon resolvases MeSH D08.811.739.900 – vdj recombinases
Sources: en.wikipedia.org
Biomedical Sciences Molecular and Cellular Biology Bioengineering and Devices Biophysics, Biochemistry and Structural Biology Climate science, Agriculture and Environment Biotechnology Regulatory Affairs, IPR and Policy
=== Hydrogen Isotope Analysis === Hydrogen isotope analysis is used to help reconstruct environmental change. Dinosterol is a particularly good target for such analysis because it is commonly found in high concentrations in a variety of aquatic environments and is well preserved in the sediment record. Hydrogen isotope analysis requires a purification method that achieves GC baseline resolution and is high yielding. Dinosterol coelutes with other sterols during GC; therefore a procedure for proper purification that involves reversed phase-high performance liquid chromatography (RP-HPLC) was developed by Atwood et al. The hydrogen isotope ratios in dinosterol can be used to reconstruct salinity semi-quantitatively. In a study by Schwab et al., the hydrogen isotope ratio of dinosterol was measured in suspended particles and surface sediments from the Chesapeake Bay estuary. The D/H ratio was found to decrease by 0.99 ± 0.23% per unit increase in salinity over the salinity range 10–29 PSU. The correlation between hydrogen isotopic response and salinity may result from diminished exchange of water between algal cells and their environment, lower growth rates and/or increased production of osmolytes at high salinities.
Raymond Ashley Fulton. For services to Music in Northern Ireland. Dr. Christine Paula Futter. Lately Chief Operating Officer, Norfolk and Suffolk Care Support Ltd. For services to Adult Social Care. Jacqueline Mary Gange. Volunteer, Cannock Chase Advice Centre. For services to the community in Cannock, Staffordshire. Nicholas George Anthony Gardner. For charitable services in Scotland. William Thomas Gavan. Mayor, Sandwell Council. For Political and Public Service, and to the LGBT+ Community. Deborah Gillian Greenslade Geany. Senior Case Manager, Personnel Recovery Unit Wales and West, Ministry of Defence. For services to Military Personnel. Syed Jason Andrew Ghaboos. Deputy Director, Civil Service Employee Experience, Cabinet Office. For Public Service. Professor Panagiotis Giannoudis. Professor of Trauma and Orthopaedics, University of Leeds and Founder, Day One Trauma Support. For services to Trauma and Orthopaedic Surgery. Dr. Dinendra Singh Gill. For services to Pre-Hospital and Trauma Care in Wales. Charity Gladstone. Lately Matron of Cardiology and Respiratory Services, Gloucestershire Hospitals NHS Foundation Trust. For services to Nursing. Jill Sylvia Gladwell. Poppy Appeal Collector. For voluntary services to the Royal British Legion in Suffolk. Judith Anne Godden. Head of Casework, Constituency Office of Tim Farron MP. For services to the community in Westmorland and Lonsdale, Cumbria. Dr. Claire Mairead Goodman. Professor of Health Care Research, Centre for Research in Public Health and Community Care, University of Hertfordshire. For services to Older People.
In 1994, National Health Laboratories acquired Allied Clinical Laboratories. The acquisition price was reduced to $204 million after federal officials issued subpoenas in an investigation of Medicare billing practices. In April 1995, Hoffmann-La Roche, a division of Roche, contributed Roche Biomedical Laboratories, Inc. and US$186.7 million in cash to National Health Laboratories Holdings, in exchange for 49.9% of the combined company. Perelman received about US$100 million from the deal, which made the new company the largest blood-testing company in the United States. The company changed its name to Laboratory Corporation of America Holdings and relocated its headquarters to Burlington, North Carolina. In July 1998, Labcorp acquired the Michigan-based laboratory division of Universal Standard Healthcare (UHCI) and made an equity investment in the company. Labcorp also became UHCI's clinical laboratory long-term testing provider but terminated this agreement in March 1999.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.